System Maintenance Notice

Please note that maintenance work is scheduled between 4 AM and 5 AM - CET. During this time, you may experience reduced performance. Thanks for your patience.

Dewi Vernerey is an expert in Oncology at Centre Hospitalier Universitaire de Besançon (France). As of August 2026, ScienceLeadR ranks Dewi Vernerey in the top 1% of experts worldwide for Intestinal Neoplasms, Colonic Diseases and Gastrointestinal Neoplasms. Dewi Vernerey has authored 284 publications, the most recent in 2026, and is an investigator in 32 clinical trials, 3 of them ongoing. SLR score: 1,323 (community average: 125). How the SLR is computed.

LeadR Profile

Dewi Vernerey Centre Hospitalier Universitaire de Besançon France
1 323 ScienceLeadR Reputation 1323

Unlock

Register Login
Network Map

Oncology

Subspecialties: Radiotherapy - Gastroenterology - Hepatology

Full career – Last 3 years

Main Topics

Publications and Clinical Studies

Publications – Clinical Studies

Profile data updated on

Expert Rankings

Top experts on the MeSH terms this expert works on

Organizations

Career arc: 2011 - 2026
Source: PubMed

Centre Hospitalier Universitaire de Besançon

Publications Synthesis

Sources: PubMed, OpenAlex

Number : 284

Citations

Citations: 9 174 1st author: 7 Last author: 22 Unique author: 0

Main journals

J Clin Oncol 53
Ann Oncol 34
Eur J Cancer 14
BMC Cancer 9
Int J Radiat Oncol Biol Phys 6

Best Journals

J Clin Oncol 36
Ann Oncol 17
Lancet Oncol 5

Breakdown by type

Click a legend label to hide or show it in the chart.

Latest Publications

5 most recent indexed articles

Source: Pubmed

Title Journal Year Citations
Adjuvant capecitabine in resected biliary tract cancer: a real-world data from the BILCAP-Real study (ACABi multicentre cohort).
PMID 42520930 — biliary tract neoplasms, neoplasms, chemotherapy, adjuvant, biliary tract, therapeutics, capecitabine		JHEP Rep20260
Regorafenib and metronomic capecitabine, cyclophosphamide, and aspirin in refractory metastatic colorectal cancer: results from the REPROGRAM-01 single-arm phase II trial.
PMID 42404549 — safety, cyclophosphamide, neoplasms, aspirin, drug therapy, colorectal neoplasms, capecitabine, chemotherapy		ESMO Gastrointest Oncol20250
Emergency integrative supportive care program for frail patients with advanced pancreatic cancer: A prospective GERCOR ARCAD study.
PMID 42396273 — quality of life, pancreatic neoplasms, emergencies, pain, neoplasms, drug therapy, fluorouracil, therapeutics, chemotherapy		medRxiv20260
Circulating tumour DNA in patients with colorectal cancer undergoing curative-intent LIver MEtastases Surgery in France: a prospective, multicentre GERCOR G-118 CLIMES PRODIGE 77 cohort study protocol.
PMID 42379715 — neoplasms, cohort studies, drug therapy, liver, neoplasm metastasis, therapeutics, colorectal neoplasms, dna, prognosis, chemotherapy		BMJ Open20260
Dual CTLA-4/PD-1 Blockade Versus Anti-PD-1 in MSI-H Metastatic Colorectal Cancer: Early Survival Benefit and Exploratory Clinical Predictors.
PMID 42285832 — neoplasms, liver, neoplasm metastasis, sex, colorectal neoplasms, msi-h		Clin Colorectal Cancer20260

Clinical Studies 32

Sources: ClinicalTrials, EU CTIS

Synthesis

By phase:

N/A 12
Phase 2 12
Phase 3 7
Phase 1/Phase 2 1

By status:

Completed 14
Active not recruiting 6
Unknown 6
Recruiting 5
Terminated 1

By type:

Interventional 24
Observational 8

By Monocentric/Multicentric:

monocentric 14
multicentric2to4 2
multicentric5to9 5
multicentricup10 11

Main Topics

Ongoing Clinical Trials

3 ongoing trials started since 2021, where this expert is an investigator

Source: ClinicalTrials

Study Phase Status Start
Evaluation of the Interest to Combine a CD4 Th1 inducer Cancer Vaccine Derived From Telomerase and Atezolizumab Plus Bevacizumab in Unresectable Hepatocellular Carcinoma
NCT05528952 — carcinoma, hepatocellular, vaccines, neoplasms, disease progression, telomerase, bevacizumab, therapeutics, cancer vaccines, vaccines, combined, carcinoma		Phase 2Recruiting2022
Prognostic and Predictive Markers of Response to Treatment in Patients With Bile Duct Cancer ACABi PRONOBIL Study
NCT04935853 — biliary tract neoplasms, bile, bile duct neoplasms, bile ducts, neoplasms, biliary tract, therapeutics		N/ARecruiting2022
Anti PD 1 and mDCF Followed by Chemoradiotherapy in Patients With Stage III Squamous Cell Anal Carcinoma
NCT04719988 — radiotherapy, cells, laboratories, blood, docetaxel, anus neoplasms, carcinoma, squamous cell, neoplasms, biopsy, drug therapy, fluorouracil, immunotherapy, chemoradiotherapy, specimen handling, biological monitoring, alphapapillomavirus, edetic acid, dna, temperature, prognosis, plasma, chemotherapy, human papillomavirus viruses, carcinoma		Phase 2Active not recruiting2022

LeadR Networks

Main global connection map

Sources: PubMed, OpenAlex, ClinicalTrials, EU CTIS